Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers
Authors
Keywords
-
Journal
International Journal of Chronic Obstructive Pulmonary Disease
Volume Volume 15, Issue -, Pages 3239-3250
Publisher
Informa UK Limited
Online
2020-12-07
DOI
10.2147/copd.s284678
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of chronic obstructive pulmonary disease: A review focusing on exacerbations
- (2020) Suzanne G Bollmeier et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Choosing the right inhaler for your asthma or COPD patient
- (2019) Omar S Usmani Therapeutics and Clinical Risk Management
- Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients
- (2019) Laurie Pahus et al. BMC Pulmonary Medicine
- Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers
- (2017) Sohini Ghosh et al. Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study
- (2017) Francesco Trotta et al. PLoS One
- Tiotropium Respimat®vs.HandiHaler®: real-life usage and TIOSPIR trial generalizability
- (2015) Sven Schmiedl et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Understanding Why Patients With COPD Get Readmitted
- (2015) Tina Shah et al. CHEST
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
- (2015) Peter C. Austin et al. STATISTICS IN MEDICINE
- Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
- (2015) Robert Wise et al. npj Primary Care Respiratory Medicine
- Tiotropium Respimat® Soft Mist™ Inhaler: A Review of Its Use in Chronic Obstructive Pulmonary Disease
- (2014) Gillian M. Keating DRUGS
- Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease
- (2013) J.M. Hohlfeld et al. JOURNAL OF CLINICAL PHARMACOLOGY
- What Proportion of Chronic Obstructive Pulmonary Disease Outpatients Is Eligible for Inclusion in Randomized Clinical Trials?
- (2013) Nicola Scichilone et al. RESPIRATION
- The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale
- (2013) Robert A Wise et al. RESPIRATORY RESEARCH
- Tiotropium Bromide Inhalation Powder
- (2012) Gillian M. Keating DRUGS
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries
- (2011) H. Quan et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now